T-Cell Acute Lymphoblastic Leukemia (T-ALL) is commonly diagnosed in
adolescents and is a rare diagnosis in children under 12 months of age.
There is little guidance regarding the details of management and
outcomes for infantile T-ALL, in particular the use of nelarabine in an
infant. Additionally, the genomic landscape of this rare oncologic
presentation has not been well documented. We present the unique
management, genomics, outcomes, and clinical course of a patient with
the diagnosis of infantile T-ALL.